Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hirao, Makoto; Tsuboi, Hideki; Nagayama, Yoshio; Kashii, Masafumi; Kaneshiro, Shoichi; Miyama, Akira; Nakaya, Hiroyuki; Kunugiza, Yasuo; Okamura, Gensuke; Etani, Yuki; Takami, Kenji; Goshima, Atsushi; Nakata, Ken

doi:https://doi.org/10.1016/j.bone.2020.115574

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

Ebina, Kosuke; Hirao, Makoto; Tsuboi, Hideki et al.

Bone, 2020, 140, 115574

アクセス数:1,177件（2025-07-17 14:26 集計）

固定URL: https://hdl.handle.net/11094/93244

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
Bone_140	pdf	なし	1.63 MB	80	2023.12.05

Creative Commons : 表示 - 非営利 - 改変禁止

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000010527708 1000010527708 著者名 Hirao, Makoto
	著者名 Tsuboi, Hideki
	著者名 Nagayama, Yoshio
	NRID 1000000576910 1000000576910 著者名 Kashii, Masafumi
	著者名 Kaneshiro, Shoichi
	著者名 Miyama, Akira
	著者名 Nakaya, Hiroyuki
	著者名 Kunugiza, Yasuo
	著者名 Okamura, Gensuke
	NRID 1000060898930 1000060898930 著者名 Etani, Yuki
	著者名 Takami, Kenji
	著者名 Goshima, Atsushi
	NRID 1000000283747 1000000283747 researchmap permalink ken-nakata ken-nakata Scopus Author ID 7402151308 7402151308 著者名 Nakata, Ken
キーワード等	Bone turnover marker
	Postmenopausal osteoporosis
	Predictor
	Prior treatment
	Romosozumab
内容	Ebina K., Hirao M., Tsuboi H., et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140, 115574 (2020); https://doi.org/10.1016/j.bone.2020.115574.
抄録	Purpose: To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n = 37) or patients previously treated with bisphosphonates (BP; n = 33), denosumab (DMAb; n = 45), or teriparatide (TPTD; n = 15) (age, 75.0 years; T-scores of the lumbar spine [LS] −3.2 and femoral neck [FN] −2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months. Results: At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P <.001 between groups) and FN BMD changes were 4.2%, 0.4%, 1.6%, and 1.5% (P =.16 between groups) for Naïve, BP, DMAb, and TPTD groups, respectively. Changes in N-terminal type I procollagen propeptide (PINP; μg/L) levels from baseline → one month were 72.7 → 139.0, 33.5 → 85.4, 30.4 → 54.3, and 98.4 → 107.4, and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b) (mU/dL) were 474.7 → 270.2, 277.3 → 203.7, 220.3 → 242.0, and 454.1 → 313.0 for Naïve, BP, DMAb, and TPTD groups, respectively. Multivariate regression analysis revealed that significant predictors of LS BMD change at six months were prior treatment difference (r = −3.1, P =.0027) and TRACP-5b percentage change (r = −2.8, P =.0071) and PINP value at one month (r = 3.2, P =.0021). Conclusion: Early effects of ROMO on the increase in LS BMD are significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. Mini abstract: Early effects of ROMO on the increase in LS BMD at six months is significantly affected by the difference of prior treatment and also predicted by the early change of bone turnover markers in patients with postmenopausal osteoporosis.
出版者	Elsevier
収録物名	Bone
巻(号)	140
ページ	115574
刊行年月	2020-11-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93244
PISSN	87563282
関連情報 (isVersionOf)	DOI (出版社版) https://doi.org/10.1016/j.bone.2020.115574
アクセス権	open access
権利情報	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
出版タイプ	Accepted Manuscript
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Bone. 2020, 140, p. 115574
DC.title	Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
DC.creator	Ebina, Kosuke
	Hirao, Makoto
	Tsuboi, Hideki
	Nagayama, Yoshio
	Kashii, Masafumi
	Kaneshiro, Shoichi
	Miyama, Akira
	Nakaya, Hiroyuki
	Kunugiza, Yasuo
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Goshima, Atsushi
	Nakata, Ken
DC.publisher	Elsevier
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-11-01
DC.identifier	https://doi.org/10.1016/j.bone.2020.115574
DC.subject	Bone turnover marker
	Postmenopausal osteoporosis
	Predictor
	Prior treatment
	Romosozumab
DC.description	Ebina K., Hirao M., Tsuboi H., et al. Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis. Bone 140, 115574 (2020); https://doi.org/10.1016/j.bone.2020.115574.
DCTERMS.abstract	Purpose: To investigate the effects of prior treatment and the predictors of early treatment response to romosozumab (ROMO) in patients with postmenopausal osteoporosis. Methods: In this prospective, observational, multicenter study, 130 treatment-naïve patients (Naïve; n = 37) or patients previously treated with bisphosphonates (BP; n = 33), denosumab (DMAb; n = 45), or teriparatide (TPTD; n = 15) (age, 75.0 years; T-scores of the lumbar spine [LS] −3.2 and femoral neck [FN] −2.9) were switched to ROMO based on their physician's decision. Bone mineral density (BMD) and serum bone turnover markers were evaluated for six months. Results: At six months, LS BMD changes were 13.6%, 7.5%, 3.6%, and 8.7% (P <.001 between groups) and FN BMD changes were 4.2%, 0.4%, 1.6%, and 1.5% (P =.16 between groups) for Naïve, BP, DMAb, and TPTD groups, respectively. Changes in N-terminal type I procollagen propeptide (PINP; μg/L) levels from baseline → one month were 72.7 → 139.0, 33.5 → 85.4, 30.4 → 54.3, and 98.4 → 107.4, and those of isoform 5b of tartrate-resistant acid phosphatase (TRACP-5b) (mU/dL) were 474.7 → 270.2, 277.3 → 203.7, 220.3 → 242.0, and 454.1 → 313.0 for Naïve, BP, DMAb, and TPTD groups, respectively. Multivariate regression analysis revealed that significant predictors of LS BMD change at six months were prior treatment difference (r = −3.1, P =.0027) and TRACP-5b percentage change (r = −2.8, P =.0071) and PINP value at one month (r = 3.2, P =.0021). Conclusion: Early effects of ROMO on the increase in LS BMD are significantly affected by the difference of prior treatment and are predicted by the early change in bone turnover markers. Mini abstract: Early effects of ROMO on the increase in LS BMD at six months is significantly affected by the difference of prior treatment and also predicted by the early change of bone turnover markers in patients with postmenopausal osteoporosis.
DC.rights	© 2020. This manuscript version is made available under the CC-BY-NC-ND 4.0 license
DC.format	93244
citation_title	Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
citation_author	Ebina, Kosuke
	Hirao, Makoto
	Tsuboi, Hideki
	Nagayama, Yoshio
	Kashii, Masafumi
	Kaneshiro, Shoichi
	Miyama, Akira
	Nakaya, Hiroyuki
	Kunugiza, Yasuo
	Okamura, Gensuke
	Etani, Yuki
	Takami, Kenji
	Goshima, Atsushi
	Nakata, Ken
citation_publisher	Elsevier
citation_language	英語
citation_date	2020-11-01
citation_journal_title	Bone
citation_volume	140
citation_firstpage	115574
citation_doi	https://doi.org/10.1016/j.bone.2020.115574
citation_public_url	https://hdl.handle.net/11094/93244

Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis

閲覧可能ファイル

論文情報

論文詳細を表示